Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: Is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission?

Journal of Clinical Oncology

Volumn 28, Issue 4, 2010, Pages 531-536

  Ehrlich, Yaron ^a   Brames, Mary J ^a   Beck, Stephen D W ^a   Foster, Richard S ^a   Einhorn, Lawrence H ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISSEMINATED CANCER; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NON SEMINOMATOUS GERMINOMA; OBSERVATION; PRIORITY JOURNAL; RETROPERITONEAL CANCER; TESTIS CANCER; TREATMENT OUTCOME; TUMOR VOLUME; LYMPHADENECTOMY; MIDDLE AGED; PATHOLOGY; REMISSION; RETROPERITONEUM; RETROSPECTIVE STUDY; TESTIS TUMOR; TIME; TUMOR RECURRENCE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; RETROPERITONEAL SPACE; RETROSPECTIVE STUDIES; TESTICULAR NEOPLASMS; TIME FACTORS; YOUNG ADULT;

EID: 77449160897     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.0714     Document Type: Article

References (26)

1. van Dijk MR, Steyerberg EW, Habbema JD: Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. Eur J Cancer 42:820-826, 2006
2. Einhorn LH, Williams SD, Loehrer PJ, et al: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 7:387-391, 1989
3. de Wit R, Stoter G, Kaye SB, et al: Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15:1837-1843, 1997
4. Vergouwe Y, Steyerberg EW, Foster RS, et al: Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: A model update and multicentre validation with more than 1000 patients. Eur Urol 51:424-432, 2007 (Pubitemid 44937791)
5. Oldenburg J, Alfsen GC, Lien HH, et al: Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 21:3310-3317, 2003 (Pubitemid 46606265)
6. Karellas M, Carver BS, Stasi J, et al: Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection for men with cII non-seminomatous germ cell tumors and a radiographically normal retroperitoneum. J Urol 177:277, 2007 (abstr 830)
7. Steiner H, Akkad T, Gozzi, et al: High rate of retroperitoneal teratoma despite complete remission after chemotherapy for metastatic nonseminomatous germ cell tumor. J Urol 177:277, 2007 (abstr 831)
8. Albers P, Weissbach L, Krege S, et al: Prediction of necrosis after chemotherapy of advanced germ cell tumors: Results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol 171:1835-1838, 2004
9. Debono DJ, Heilman DK, Einhorn LH, et al: Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 15:1455-1464, 1997
10. Motzer RJ, Nichols CJ, Margolin KA, et al: Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25:247-256, 2007
11. Nichols CR, Williams SD, Loehrer PJ, et al: Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9:1163-1172, 1991
12. Pan C, Brames M, Dobrolecki L, et al: SELDI may facilitate the management of germ cell tumor. J Clin Oncol 23:397s, 2005 (suppl; abstr 4580)
13. International Germ Cell Cancer Collaborative Group: International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594-603, 1997
14. Hill ME, Rosenwaike I: The Social Security Administration's Death Master File: The completeness of death reporting at older ages. Soc Secur Bull 64:45-51, 2001-2002
15. Loehrer PJ Sr, Johnson D, Elson P, et al: Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial. J Clin Oncol 13:470-476, 1995
16. Sonneveld DJ, Sleijfer DT, Koops HS, et al: Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: A plea for an aggressive surgical approach. Cancer 82:1343-1351, 1998
17. Hendry WF, Norman AR, Dearnaley DP, et al: Metastatic nonseminomatous germ cell tumors of the testis: Results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 94:1668-1676, 2002
18. Nichols CR, Moore CJ, Cho BL, et al: Management of chemotherapy-induced remissions in patients with disseminated nonseminomatous germ cell tumors: A review of 98 consecutive patients. J Clin Oncol 26:258s, 2008 (suppl; abstr 5037)
19. Kakiashvili D, Anson-Cartwright L, Moore M, et al: Post-chemotherapy retroperitoneal lymph node dissection for testicular germ cell tumors: Is surgery indicated in all and is bilateral template necessary? Princess Margaret Hospital experience. J Urol 181:325, 2009 (abstr 911)
20. Carver BS, Shayegan B, Serio A, et al: Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol 25:1033-1037, 2007
21. Baniel J, Foster RS, Gonin R, et al: Late relapse of testicular cancer. J Clin Oncol 13:1170-1176, 1995
22. Sharp DS, Carver BS, Eggener SE, et al: Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol 26:5524-5529, 2008
23. Culine S, Kerbrat P, Kramar A, et al: Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: A randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 18:917-924, 2007
24. Albers P, Siener R, Krege S, et al: Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 26:2966-2972, 2008
25. Beck SDW, Foster RS, Bihrle R, et al: Long term outcome for patients with high volume retroperitoneal teratoma undergoing post chemotherapy surgery. J Urol 181:2526-2532, 2009
26. Beck SD, Foster RS, Bihrle R, et al: Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer. J Urol 168:1402-1404, 2002 (Pubitemid 35034131)